Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2023 08:00 ET | Source: APIE Therapeutics

APIE Therapeutics Appoints Ashwin Datt Chief Executive Officer

Research Triangle Park, NC, July 11, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical regenerative medicines company, today announced the appointment of industry veteran, Ashwin...
March 21, 2023 08:00 ET | Source: APIE Therapeutics

APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors

Cary, NC, March 21, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced...
August 30, 2022 08:00 ET | Source: APIE Therapeutics

APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis

CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...
August 02, 2022 10:15 ET | Source: APIE Therapeutics

APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis

Cary, NC, Aug. 02, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor (APJ),...
January 12, 2022 07:30 ET | Source: APIE Therapeutics

APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer

Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
March 18, 2021 08:11 ET | Source: APIE Therapeutics

APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer

Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...